{"id":390697,"date":"2018-04-25T00:00:00","date_gmt":"2018-04-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0010-2018-biopharma-atopic-dermatitis-unmet-need-moderate-to-severe-us-eu-2018\/"},"modified":"2026-05-02T23:37:46","modified_gmt":"2026-05-02T23:37:46","slug":"unneim0010-2018-biopharma-atopic-dermatitis-unmet-need-moderate-to-severe-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0010-2018-biopharma-atopic-dermatitis-unmet-need-moderate-to-severe-us-eu-2018\/","title":{"rendered":"Atopic Dermatitis | Unmet Need | Moderate to Severe | US\/EU | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>\u00a0market is at the beginning of a revolution with the recent approval of the first targeted <abbr title=\"atopic dermatitis\">AD<\/abbr> biologic, Sanofi\/Regeneron\u2019s Dupixent, and a promising suite of mid-stage agents (e.g., Novartis\u2019s ZPL-389, Galderma\u2019s nemolizumab, AbbVie\u2019s upadacitinib) and late-stage agents (e.g., Eli Lilly\u2019s baricitinib, Pfizer\u2019s PF-04965842, LEO Pharma\u2019s tralokinumab) advancing in the pipeline. In this report, we assess the commercial opportunity remaining in the topical-refractory, moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr> space through a comprehensive look at dermatologists\u2019 treatment goals; the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the appeal of new <abbr title=\"atopic dermatitis\">AD<\/abbr> products.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for topical-refractory, moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for topical-refractory, moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in topical-refractory, moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists\u00a0for a hypothetical new drug for topical-refractory, moderate to severe <abbr title=\"atopic dermatitis\">AD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, and Germany.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61\u00a0U.S. and 30\u00a0European dermatologists\u00a0fielded in March 2018.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Dermira, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, and Vanda.<\/p>\n<p><strong>Key drugs: <\/strong>Dupixent, Olumiant, lebrikizumab, nemolizumab, PF-04965842, tralokinumab, tradipitant,\u00a0upadacitinib, and ZPL-389.<\/p>\n","protected":false},"template":"","class_list":["post-390697","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390697\/revisions"}],"predecessor-version":[{"id":393821,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390697\/revisions\/393821"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}